LivagenvsMOTS-C

Livagen is a short tripeptide (Lys-Glu-Asp) within the Khavinson bioregulator family — peptides hypothesised to regulate gene expression in tissue-specific ways by binding to gene promoter regions. Livagen is positioned as the liver-targeted member of this family, intended to modulate hepatocyte gene expression in ways that support liver regeneration and counteract age-related decline in hepatic function.

Proposed mechanisms include modulation of chromatin condensation states in hepatocyte and lymphocyte nuclei, upregulation of genes involved in hepatic detoxification pathways (cytochrome P450 enzymes, glutathione synthesis), and immunomodulatory effects in liver-resident immune cells. Russian research has reported livagen-induced increases in hepatocyte regeneration markers in animal models of liver injury and changes in lymphocyte chromatin organisation consistent with cellular rejuvenation.

As with all Khavinson tripeptides, the proposed action model is that livagen acts as a transient signalling molecule triggering longer-lasting changes in gene expression. Plasma exposure is brief (around 30 minutes) but downstream transcriptional effects are claimed to persist for weeks, justifying pulse-dosing protocols of 10-30 day courses repeated periodically. The evidence base for clinical efficacy is dominated by Russian gerontology research with limited independent Western replication, and clinical use outside Russia remains largely anecdotal. Livagen should not be used as a substitute for evidence-based liver disease management.

MOTS-C (Mitochondrial Open Reading Frame of the Twelve S rRNA type-C) is a 16-amino-acid peptide encoded in the mitochondrial genome within the 12S rRNA gene. Its discovery in 2015 by Dr. Changhan David Lee at USC was groundbreaking because it demonstrated that the mitochondrial genome encodes functional peptides beyond the 13 oxidative phosphorylation subunits traditionally recognized — establishing mitochondria as endocrine organelles capable of producing signaling hormones.

MOTS-C's primary metabolic mechanism centers on activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. MOTS-C activates AMPK by increasing the AMP/ATP ratio through inhibition of the folate cycle and de novo purine biosynthesis pathway. Specifically, MOTS-C inhibits the folate/methionine cycle enzyme ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase), leading to accumulation of the intermediate AICAR — which is itself an endogenous AMPK activator. This creates a feed-forward AMPK activation signal.

Activated AMPK triggers a cascade of metabolic adaptations that mimic exercise: increased glucose uptake via GLUT4 translocation (independent of insulin signaling), enhanced fatty acid oxidation through ACC phosphorylation and CPT-1 activation, stimulation of mitochondrial biogenesis via PGC-1α, and suppression of mTORC1-mediated protein synthesis to conserve energy. Under metabolic stress, MOTS-C translocates from the cytoplasm to the nucleus — a remarkable feat for a mitochondria-encoded peptide — where it directly regulates nuclear gene expression by interacting with antioxidant response elements (AREs) and NF-κB target genes. This nuclear translocation represents a novel mechanism of mitonuclear communication — the mitochondria literally sending a peptide messenger to the nucleus to coordinate the cellular stress response. MOTS-C levels decline with age in humans, correlating with the age-related decline in metabolic fitness, insulin sensitivity, and exercise capacity, making it a compelling target for metabolic aging intervention.